Ultragenyx Pharmaceutical Inc. (RARE) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$673.0M

Net Income/Loss (FY2025)

-$575.0M

Total Assets (FY2025)

$1.5B

Total Equity (FY2025)

-$73.0M

Cash Flows from Operating Activities (FY2025)

-$466.0M

Source: Ultragenyx Pharmaceutical Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.